Novo Nordisk advances obesity pipeline with early-stage oral drug trial from Lexicon deal
Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders....
Stocktwits